Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL 1383I TCR Therapy for Advanced Melanoma
NCT02870244Phase 1Recruiting
- Sponsor
- Loyola University Chicago
- Start
- Feb 2015
- Primary completion
- Sep 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TIL 1383I TCR transduced T cells in melanoma, sponsored by Loyola University Chicago. Primary endpoint: Grade 2 through Grade 5 Adverse Events at 4 weeks. Started Feb 2015; status: recruiting.
02
Drugs
TIL 1383I TCR transduced T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02870244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870244.